PL116228B1 - Process for preparing novel derivatives of 4"-desoxyaminoerythromycin a" - Google Patents

Process for preparing novel derivatives of 4"-desoxyaminoerythromycin a" Download PDF

Info

Publication number: PL116228B1
Authority: PL; Poland
Prior art keywords: formula; compound; group; hydrogen atom; hydrogen
Prior art date: 1977-02-04

Application number

PL1978204428A

Other languages

English (en)

Polish (pl)

Other versions

PL204428A1 (pl

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-02-04

Filing date

1978-02-03

Publication date

1981-05-30

1977-12-01 Priority claimed from US05/856,479 external-priority patent/US4150220A/en

1978-02-03 Application filed by Pfizer filed Critical Pfizer

1979-06-04 Publication of PL204428A1 publication Critical patent/PL204428A1/xx

1981-05-30 Publication of PL116228B1 publication Critical patent/PL116228B1/pl

Links

238000004519 manufacturing process Methods 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims description 104
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 67
239000002253 acid Substances 0.000 claims description 57
150000003839 salts Chemical class 0.000 claims description 49
125000004432 carbon atom Chemical group C* 0.000 claims description 37
230000002829 reductive effect Effects 0.000 claims description 32
238000000034 method Methods 0.000 claims description 28
239000001257 hydrogen Substances 0.000 claims description 27
229910052739 hydrogen Inorganic materials 0.000 claims description 27
150000003863 ammonium salts Chemical class 0.000 claims description 19
229910052799 carbon Inorganic materials 0.000 claims description 14
238000009833 condensation Methods 0.000 claims description 14
230000005494 condensation Effects 0.000 claims description 14
150000002431 hydrogen Chemical group 0.000 claims description 14
238000011065 in-situ storage Methods 0.000 claims description 14
125000004430 oxygen atom Chemical group O* 0.000 claims description 13
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
238000006722 reduction reaction Methods 0.000 claims description 9
238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 6
238000010531 catalytic reduction reaction Methods 0.000 claims description 6
229910052987 metal hydride Inorganic materials 0.000 claims description 6
150000004681 metal hydrides Chemical class 0.000 claims description 6
-1 alkane carboxylic acid Chemical class 0.000 claims description 5
208000013840 Non-involuting congenital hemangioma Diseases 0.000 claims description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
229910052716 thallium Inorganic materials 0.000 claims description 2
238000006555 catalytic reaction Methods 0.000 claims 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 73
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 72
239000000047 product Substances 0.000 description 69
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
239000000203 mixture Substances 0.000 description 41
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 36
239000000243 solution Substances 0.000 description 36
239000010410 layer Substances 0.000 description 30
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 26
239000002904 solvent Substances 0.000 description 22
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 20
229910052938 sodium sulfate Inorganic materials 0.000 description 20
235000011152 sodium sulphate Nutrition 0.000 description 20
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 18
238000006243 chemical reaction Methods 0.000 description 17
239000000284 extract Substances 0.000 description 17
150000002923 oximes Chemical class 0.000 description 13
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 12
239000012044 organic layer Substances 0.000 description 11
238000003756 stirring Methods 0.000 description 11
239000003054 catalyst Substances 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
229960003276 erythromycin Drugs 0.000 description 9
238000002844 melting Methods 0.000 description 9
230000008018 melting Effects 0.000 description 9
244000005700 microbiome Species 0.000 description 9
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 8
239000005695 Ammonium acetate Substances 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
235000019257 ammonium acetate Nutrition 0.000 description 8
229940043376 ammonium acetate Drugs 0.000 description 8
239000000706 filtrate Substances 0.000 description 8
150000001412 amines Chemical group 0.000 description 7
230000000844 anti-bacterial effect Effects 0.000 description 7
239000012298 atmosphere Substances 0.000 description 7
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
239000007868 Raney catalyst Substances 0.000 description 6
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 6
229910000564 Raney nickel Inorganic materials 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 6
238000002425 crystallisation Methods 0.000 description 6
230000008025 crystallization Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000006260 foam Substances 0.000 description 6
239000013505 freshwater Substances 0.000 description 6
150000002576 ketones Chemical class 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
239000012452 mother liquor Substances 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000001953 recrystallisation Methods 0.000 description 5
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
229930006677 Erythromycin A Natural products 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
239000013543 active substance Substances 0.000 description 4
125000002252 acyl group Chemical group 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000000605 extraction Methods 0.000 description 4
230000002349 favourable effect Effects 0.000 description 4
150000002466 imines Chemical class 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
229960005261 aspartic acid Drugs 0.000 description 3
239000006227 byproduct Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
IDRYSCOQVVUBIJ-PPGFLMPOSA-N erythromycin B Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@H]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)C)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 IDRYSCOQVVUBIJ-PPGFLMPOSA-N 0.000 description 3
238000005984 hydrogenation reaction Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000013067 intermediate product Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
230000007017 scission Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
239000000725 suspension Substances 0.000 description 3
YHVUVJYEERGYNU-UHFFFAOYSA-N 4',8-Di-Me ether-5,7,8-Trihydroxy-3-(4-hydroxybenzyl)-4-chromanone Natural products COC1(C)CC(O)OC(C)C1O YHVUVJYEERGYNU-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
101150041968 CDC13 gene Proteins 0.000 description 2
ZOYWWAGVGBSJDL-UHFFFAOYSA-N D-desosamine Natural products CC1CC(N(C)C)C(O)C(O)O1 ZOYWWAGVGBSJDL-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
AJSDVNKVGFVAQU-BIIVOSGPSA-N cladinose Chemical compound O=CC[C@@](C)(OC)[C@@H](O)[C@H](C)O AJSDVNKVGFVAQU-BIIVOSGPSA-N 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
VTJCSBJRQLZNHE-CSMHCCOUSA-N desosamine Chemical compound C[C@@H](O)C[C@H](N(C)C)[C@@H](O)C=O VTJCSBJRQLZNHE-CSMHCCOUSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000009931 harmful effect Effects 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
239000012535 impurity Substances 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000003120 macrolide antibiotic agent Substances 0.000 description 2
239000012299 nitrogen atmosphere Substances 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
101150032584 oxy-4 gene Proteins 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
230000036632 reaction speed Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000003797 solvolysis reaction Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
XCLJRCAJSCMIND-JCTYMORFSA-N (9S)-erythromycyclamine Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)[C@@H](N)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 XCLJRCAJSCMIND-JCTYMORFSA-N 0.000 description 1
LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 1
YEYKMVJDLWJFOA-UHFFFAOYSA-N 2-propoxyethanol Chemical compound CCCOCCO YEYKMVJDLWJFOA-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
IDRYSCOQVVUBIJ-UHFFFAOYSA-N Erythromycin-B Natural products CC1C(OC2C(C(CC(C)O2)N(C)C)O)C(C)(O)CC(C)C(=O)C(C)C(O)C(C)C(CC)OC(=O)C(C)C1OC1CC(C)(OC)C(O)C(C)O1 IDRYSCOQVVUBIJ-UHFFFAOYSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229910052774 Proactinium Inorganic materials 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000012267 brine Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000000249 desinfective effect Effects 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
229950001028 erythromycin propionate Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000012259 ether extract Substances 0.000 description 1
239000002024 ethyl acetate extract Substances 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
229950006191 gluconic acid Drugs 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
229940071870 hydroiodic acid Drugs 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000000155 melt Substances 0.000 description 1
230000003641 microbiacidal effect Effects 0.000 description 1
229940124561 microbicide Drugs 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000003973 paint Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
238000004321 preservation Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000010956 selective crystallization Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000012265 solid product Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000001665 trituration Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000001018 virulence Effects 0.000 description 1
239000002023 wood Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Animal Behavior & Ethology (AREA)
Communicable Diseases (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL1978204428A 1977-02-04 1978-02-03 Process for preparing novel derivatives of 4"-desoxyaminoerythromycin a" PL116228B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US76548077A	1977-02-04	1977-02-04
US05/856,479 US4150220A (en)	1977-02-04	1977-12-01	Semi-synthetic 4"-erythromycin A derivatives

Publications (2)

Publication Number	Publication Date
PL204428A1 PL204428A1 (pl)	1979-06-04
PL116228B1 true PL116228B1 (en)	1981-05-30

Family

ID=27117613

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL1978204428A PL116228B1 (en)	1977-02-04	1978-02-03	Process for preparing novel derivatives of 4"-desoxyaminoerythromycin a"

Country Status (30)

Country	Link
JP (1)	JPS5827798B2 (el)
AR (1)	AR222147A1 (el)
AU (1)	AU501298B1 (el)
BG (2)	BG32718A3 (el)
CA (1)	CA1106367A (el)
CH (1)	CH628906A5 (el)
CS (1)	CS221801B2 (el)
DD (1)	DD140048A5 (el)
DE (1)	DE2804507C2 (el)
DK (1)	DK148036C (el)
ES (2)	ES466057A1 (el)
FI (1)	FI780354A (el)
FR (2)	FR2379550A1 (el)
GB (2)	GB1585315A (el)
GR (1)	GR68691B (el)
HU (1)	HU182559B (el)
IE (1)	IE46661B1 (el)
IL (2)	IL53968A0 (el)
IT (1)	IT1094209B (el)
LU (1)	LU79004A1 (el)
NL (1)	NL176174C (el)
NO (2)	NO146472C (el)
NZ (1)	NZ186385A (el)
PH (2)	PH14421A (el)
PL (1)	PL116228B1 (el)
PT (1)	PT67568B (el)
RO (4)	RO77345A (el)
SE (2)	SE445223B (el)
SU (1)	SU927122A3 (el)
YU (3)	YU40913B (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4124755A (en) *	1978-01-03	1978-11-07	Pfizer Inc.	11-Alkanoyl-4"-deoxy-4"-isonitrilo-oleandomycin derivatives
US4133950A (en) *	1978-01-03	1979-01-09	Pfizer Inc.	4"-Deoxy-4"-carbamate and dithiocarbamate derivatives of oleandomycin and its esters
US4382085A (en) *	1982-03-01	1983-05-03	Pfizer Inc.	4"-Epi erythromycin A and derivatives thereof as useful antibacterial agents
US4518590A (en) *	1984-04-13	1985-05-21	Pfizer Inc.	9α-Aza-9α-homoerythromycin compounds, pharmaceutical compositions and therapeutic method
HN1998000074A (es) *	1997-06-11	1999-01-08	Pfizer Prod Inc	Derivados de macrolidos c-4 sustituidos
US6407074B1 (en)	1997-06-11	2002-06-18	Pfizer Inc	C-4″-substituted macrolide derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3836519A (en) *	1973-05-04	1974-09-17	Abbott Lab	Sulfonyl derivatives of erythromycin
US3884903A (en) *	1973-06-21	1975-05-20	Abbott Lab	4{41 -Deoxy-4{41 -oxoerythromycin B derivatives

1978
- 1978-01-10 SE SE7800270A patent/SE445223B/sv not_active IP Right Cessation
- 1978-01-13 PH PH20662A patent/PH14421A/en unknown
- 1978-01-17 ES ES466057A patent/ES466057A1/es not_active Expired
- 1978-01-18 YU YU73/78A patent/YU40913B/xx unknown
- 1978-01-18 AR AR270752A patent/AR222147A1/es active
- 1978-01-23 PT PT67568A patent/PT67568B/pt unknown
- 1978-01-31 CH CH106178A patent/CH628906A5/fr not_active IP Right Cessation
- 1978-02-02 RO RO7893080A patent/RO77345A/ro unknown
- 1978-02-02 CA CA296,037A patent/CA1106367A/en not_active Expired
- 1978-02-02 RO RO78101651A patent/RO79687A7/ro unknown
- 1978-02-02 RO RO78101650A patent/RO79686A7/ro unknown
- 1978-02-02 GB GB4165/78A patent/GB1585315A/en not_active Expired
- 1978-02-02 CS CS78703A patent/CS221801B2/cs unknown
- 1978-02-02 GR GR55330A patent/GR68691B/el unknown
- 1978-02-02 DE DE2804507A patent/DE2804507C2/de not_active Expired
- 1978-02-02 RO RO105255A patent/RO81622B/ro unknown
- 1978-02-02 GB GB34309/79A patent/GB1585316A/en not_active Expired
- 1978-02-03 NZ NZ186385A patent/NZ186385A/xx unknown
- 1978-02-03 SU SU782573754A patent/SU927122A3/ru active
- 1978-02-03 DK DK51878A patent/DK148036C/da not_active IP Right Cessation
- 1978-02-03 PL PL1978204428A patent/PL116228B1/pl unknown
- 1978-02-03 BG BG038579A patent/BG32718A3/xx unknown
- 1978-02-03 JP JP53011352A patent/JPS5827798B2/ja not_active Expired
- 1978-02-03 DD DD78203547A patent/DD140048A5/de unknown
- 1978-02-03 LU LU79004A patent/LU79004A1/xx unknown
- 1978-02-03 FR FR7803066A patent/FR2379550A1/fr active Granted
- 1978-02-03 BG BG040069A patent/BG33159A3/xx unknown
- 1978-02-03 IT IT20005/78A patent/IT1094209B/it active
- 1978-02-03 HU HU78PI611A patent/HU182559B/hu not_active IP Right Cessation
- 1978-02-03 IL IL53968A patent/IL53968A0/xx not_active IP Right Cessation
- 1978-02-03 NO NO780389A patent/NO146472C/no unknown
- 1978-02-03 AU AU32990/78A patent/AU501298B1/en not_active Expired
- 1978-02-03 NL NLAANVRAGE7801262,A patent/NL176174C/xx not_active IP Right Cessation
- 1978-02-03 FI FI780354A patent/FI780354A/fi not_active Application Discontinuation
- 1978-02-03 IE IE239/78A patent/IE46661B1/en not_active IP Right Cessation
- 1978-07-07 FR FR7820334A patent/FR2385735A1/fr active Granted
- 1978-08-08 ES ES472429A patent/ES472429A1/es not_active Expired
- 1978-09-01 PH PH21555A patent/PH16675A/en unknown
1981
- 1981-01-27 IL IL61997A patent/IL61997A0/xx unknown
- 1981-06-05 NO NO811913A patent/NO150484C/no unknown
1983
- 1983-02-07 YU YU265/83A patent/YU40798B/xx unknown
- 1983-02-16 SE SE8300870A patent/SE457086B/xx not_active IP Right Cessation
- 1983-11-21 YU YU2279/83A patent/YU40799B/xx unknown

Also Published As

Publication number	Publication date
SE8300870D0 (sv)	1983-02-16
IE780239L (en)	1978-08-04
FR2379550A1 (fr)	1978-09-01
YU7378A (en)	1983-04-30
NO150484B (no)	1984-07-16
LU79004A1 (fr)	1979-09-06
YU40798B (en)	1986-06-30
NL176174C (nl)	1985-03-01
NZ186385A (en)	1980-10-08
FR2385735A1 (fr)	1978-10-27
GR68691B (el)	1982-02-01
AU501298B1 (en)	1979-06-14
BG33159A3 (en)	1982-12-15
DK148036B (da)	1985-02-11
PL204428A1 (pl)	1979-06-04
NO146472B (no)	1982-06-28
IT7820005A0 (it)	1978-02-03
SE8300870L (sv)	1983-02-16
RO81622B (ro)	1983-04-30
PH14421A (en)	1981-07-10
NO811913L (no)	1978-08-07
IL53968A0 (en)	1978-04-30
FI780354A (fi)	1978-08-05
DK148036C (da)	1985-07-15
SE7800270L (sv)	1978-08-05
CA1106367A (en)	1981-08-04
AR222147A1 (es)	1981-04-30
IL61997A0 (en)	1981-02-27
SE445223B (sv)	1986-06-09
RO81622A (ro)	1983-04-29
DE2804507A1 (de)	1978-08-10
JPS53101337A (en)	1978-09-04
YU227983A (en)	1984-04-30
YU40799B (en)	1986-06-30
DD140048A5 (de)	1980-02-06
GB1585315A (en)	1981-02-25
NO146472C (no)	1982-10-06
YU26583A (en)	1984-02-29
YU40913B (en)	1986-08-31
RO79686A7 (ro)	1982-08-17
FR2379550B1 (el)	1980-07-04
NL7801262A (nl)	1978-08-08
JPS5827798B2 (ja)	1983-06-11
BG32718A3 (en)	1982-09-15
SU927122A3 (ru)	1982-05-07
CS221801B2 (en)	1983-04-29
ES472429A1 (es)	1979-04-01
IT1094209B (it)	1985-07-26
NO780389L (no)	1978-08-07
RO77345A (ro)	1981-08-17
SE457086B (sv)	1988-11-28
DK51878A (da)	1978-08-05
RO79687A7 (ro)	1982-08-17
NL176174B (nl)	1984-10-01
PT67568A (en)	1978-02-01
FR2385735B1 (el)	1980-10-24
ES466057A1 (es)	1978-10-01
PH16675A (en)	1983-12-13
GB1585316A (en)	1981-02-25
NO150484C (no)	1984-10-24
CH628906A5 (en)	1982-03-31
DE2804507C2 (de)	1982-11-04
PT67568B (en)	1979-06-18
IE46661B1 (en)	1983-08-24
HU182559B (en)	1984-02-28

Publication	Publication Date	Title
JP3083102B2 (ja)	2000-09-04	エリスロマイシンおよびアジスロマイシンの３”−デスメトキシ誘導体
FI72980B (fi)	1987-04-30	Foerfarande foer framstaellning av 4ç-epi-9-deoxo-9a-metyl-9a-aza-9a-homoerytromycin a och dess farmaceutiskt godtagbara salter samt mellanprodukterna anvaenda i foerfarandet.
US5869629A (en)	1999-02-09	Synthesis of 9-deoxo-9a-aza-11,12-deoxy-9a-methyl-9a-homoerythromycin A 11,12 Hydrogenorthoborate dihydrate and a process for the preparation of azitromicin dihydrate
US4526889A (en)	1985-07-02	Epimeric azahomoerythromycin A derivative, intermediates and method of use
US4150220A (en)	1979-04-17	Semi-synthetic 4"-erythromycin A derivatives
NZ203417A (en)	1985-10-11	4"-epi-erythromycin a and derivatives and pharmaceutical compositions
PL116228B1 (en)	1981-05-30	Process for preparing novel derivatives of 4"-desoxyaminoerythromycin a"
SE447118B (sv)	1986-10-27	4"-deoxi-4"-acylamido-derivat av oleandomyciner, erytromyciner och erytromycinkarbonat
EP0503932A1 (en)	1992-09-16	9-Deoxo-9(z)-hydroxy-iminoerythromycin A and O-derivatives thereof
EP0503949A1 (en)	1992-09-16	Novel process for the preparation of 9-deoxo-9(z)-hydroxyiminoerythromycin A
CA1106366A (en)	1981-08-04	Semi-synthetic 4"-amino-oleandomycin derivatives
EP0136831A2 (en)	1985-04-10	Azahomoerythromycin B derivatives and intermediates thereof
IE56567B1 (en)	1991-09-11	Alkylation of oleandomycin
FI68404C (fi)	1985-09-10	Foerfarande foer framstaellning av terapeutiskt anvaendbara 4"deoxi-4"-aminoerytromycin-a-derivat
DK148421B (da)	1985-07-01	Analogifremgangsmaade til fremstilling af 4''-deoxy-4''-(substitueret)amino-oleandomycinderivater eller salte deraf
CA1250284A (en)	1989-02-21	Antibacterial epimeric azahomoerythromycin a derivative and production thereof
CA1128506A (en)	1982-07-27	Semi-synthetic 4"-erythromycin a derivatives
GB1590162A (en)	1981-05-28	Oleandomycin derivatives
MXPA97005190A (en)	1998-01-01	Synthesis of 11,12-hydrogenoborate of 9-desoxy-9a-aza-11,12-desoxy-9a-methyl-9a-homoeritromycin a. a procedure for the preparation of 9-desoxy-9a-aza-9a-methyl-9a -homoeritromycin a dihydrate (azitromycin dihydra
MXPA98009308A (en)	1999-07-06	Derivatives of 3-descladinosa-2, 3-anhydroeritromic
EP1479687A1 (en)	2004-11-24	Novel 15-membered cyclic azalide, novel 16-membered cyclic diazalide derivative, and process for producing these
MXPA00002216A (en)	2001-03-05	3-descladinose 6-o-substituded erythromycin derivatives
CS241099B2 (cs)	1986-03-13	Způsob přípravy 4“-epi-9-deoxo-9a-methyl-9a-aza- -9a-bomoerythromycinu A